We claim:

1. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H_3 receptor antagonist / m_2 muscarinic antagonist.

2. The method of claim 1 wherein the dual H_3/m_2 antagonist is selected from the group consisting of


,


,


,


,


,


,


,


,


,


,


,



,



,



and



.

3. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a combination of an histamine H_3 receptor antagonist and a m_2 muscarinic antagonist.

4. The method of claim 3 wherein the histamine H_3 receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam, SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX.

5. The method of claim 4 wherein the histamine H_3 antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX.

6. The method of claim 3 wherein the m_2 muscarinic antagonist is selected from the compounds of the formula IA-1.

7. The method of claim 6 wherein the histamine H_3 receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam,

SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX.

8. The method of claim 7 wherein the histamine H_3 antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX.

9. The method of claim 3 wherein the histamine H_3 antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX, and the m_2 antagonist is



10. A pharmaceutical composition comprising an effective amount of a combination of a histamine H_3 antagonist and a m_2 muscarinic antagonist, and a pharmaceutically acceptable carrier.

11. The composition of claim 10 wherein the histamine H_3 receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam, SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX; and wherein the m_2 muscarinic antagonist is selected from the compounds of formula IA-1.

12. The composition of claim 11 wherein the histamine H_3 antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX and the m_2 antagonist is



13. A kit comprising in a single package, one container comprising a histamine H_3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising a m_2 muscarinic antagonist in a pharmaceutically acceptable carrier, with

the H_3 and m_2 antagonists being present in amounts such that the combination is effective to treat cognition deficit disorders.

14. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H_3 antagonist/m_2 muscarinic antagonist or an effective amount of a combination of a histamine H_3 receptor antagonist and a m_2 muscarinic antagonist, in combination with an effective amount of an acetylcholinesterase inhibitor.

15. A pharmaceutical composition comprising an effective amount of a dual histamine H_3 antagonist/ m_2 muscarinic antagonist or a combination of a histamine H_3 antagonist and a m_2 muscarinic antagonist, in further combination with an acetylcholinesterase inhibitor and a pharmaceutically acceptable carrier.

16. A kit comprising, in a single package, one container comprising a dual histamine H_3 antagonist/ m_2 muscarinic antagonist in a pharmaceutically acceptable carrier, or separate containers comprising a histamine H_3 antagonist in a pharmaceutically acceptable carrier and a m_2 muscarinic antagonist in a pharmaceutically acceptable carrier, and another container comprising an acetylcholinesterase inhibitor in a pharmaceutically acceptable carrier.